Blog

Scientists Don’t Fear a New Crispr Snag – Bloomberg


Bloomberg

Scientists Don't Fear a New Crispr Snag
Bloomberg
Porteus himself is working with FDA to start clinical trials of a Crispr-based therapy for sickle cell disease. The key difference between Crispr and more traditional gene therapy, he said, is in its precision. The original version of gene therapy
China Is Way Ahead When It Comes To CRISPR Gene EditingIFLScience


CRISPR first in US: Human cancer patients to be treated with gene-editing toolGenetic Literacy Project

all 5 news articles »

2018-01-23 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.